REG - Avacta Group PLC - Appointment of Joint Broker

AvactaAnnouncement

04/02/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250204:nRSD7481Va&default-theme=true

RNS Number : 7481V  Avacta Group PLC  04 February 2025

 

Avacta Group plc

 

("Avacta" or the "Group" or the "Company")

 

Appointment of Joint Broker

 

 

LONDON and PHILADELPHIA - February 4, 2025 - Avacta Therapeutics (AIM: AVCT),
a life sciences company developing next generation peptide drug conjugates
(PDC) targeting powerful anti-tumor payloads directly to the tumor, today
announced the appointment of Panmure Liberum Limited ("Panmure Liberum") as
its joint broker with immediate effect. Panmure Liberum will work alongside
Peel Hunt, the Company's Nominated Adviser and existing corporate broker.

 

 

 

-Ends-

 

 

For further information from Avacta, please contact:

 

 Avacta Group plc                                           avacta.com (http://avacta.com/)

 Michael Vinegrad, Group Communications

 Director

 Peel Hunt (Nomad and Joint Broker)

 James Steel / Chris Golden / Patrick Birkholm              www.peelhunt.com (http://www.peelhunt.com/)

 Panmure Liberum (Joint Broker)                             www.panmureliberum.com (https://panmureliberum.com/)

 Emma Earl, Will Goode, Mark Rogers

 David Cox (Healthcare Specialist Sales)

 ICR Healthcare

 Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert   avacta@consilium-comms.com (mailto:avacta@consilium-comms.com)

 Investor and Communications Contact

 Renee Leck

 THRUST Strategic Communications                            www.thruststrategiccommunications.com

                                                          (http://www.thruststrategiccommunications.com)

 Media Contact

 Carly Scaduto                                              Carly@carlyscadutoconsulting.com

                                                          (https://www.globenewswire.com/Tracker?data=YG-jwixFWaHByFwlhEr4NbVmhGc9YbrV0ozbiHY-33jDG-KDtaZDvqBLS4-5RgIi5zejtwvrLPO1U6xSYlV9BnK-dIegbuZft6wwj-ugstEWYrPDSrd9NwgKYBdm1l9Ty6VSa1gsRJqxeLaMfUN-easXzPVocBafm0xbzTKFahId-T7w4WgPYGYfKdFh6MGXNNniX0b0LrpQwjqHYj_mTmjerN3nRW6pwlbWejQ6wZCns0oke-U-WA7CB-Z2CD1ObedcWrqwKYgQwTY1NxAOLXtmHTL3VJ7HZ4Z3K9ZhB_2_vgbo4aKKTppE6l1bjU2w)
 Carly Scaduto Consulting

 

 

About Avacta - http://avacta.com/ (http://avacta.com/)

Avacta Therapeutics is a clinical-stage life sciences company expanding the
reach of highly potent cancer therapies with the pre|CISION(®) platform.
pre|CISION(®) is a proprietary warhead delivery system based on a
tumor-specific protease (fibroblast activation protein or FAP) that is
designed to concentrate highly potent warheads in the tumor microenvironment
while sparing normal tissues. Our innovative pipeline consists of
pre|CISION(®) peptide drug conjugates (PDC) or Affimer(®) drug conjugates
(AffDC) that leverage the tumor-specific release mechanism, providing unique
benefits over traditional antibody drug conjugates.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPSSWESDEISEFE